Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2511–2517. doi: 10.1128/aac.41.11.2511

Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

D J Occhipinti 1, S L Pendland 1, L L Schoonover 1, E B Rypins 1, L H Danziger 1, K A Rodvold 1
PMCID: PMC164153  PMID: 9371358

Abstract

The pharmacokinetics and pharmacodynamics of two multiple-dose regimens of piperacillin-tazobactam (3.375 g every 6 h and 4.5 g every 8 h) were evaluated at steady state for 12 healthy adult volunteers. Inhibitory and bactericidal activities for the two regimens were determined with five American Type Culture Collection (ATCC) organisms (Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Bacteroides fragilis). The percentage of time that plasma concentrations remained above the MIC (T > MIC) for each organism and dosage regimen was calculated. Areas under the inhibitory (AUIC0-24) and bactericidal activity (AUBC0-24) curves were calculated with the trapezoidal rule by using the reciprocal of the inhibitory and bactericidal titers determined for each dosage regimen. In order to assess the validity of predicted measures of bactericidal (AUC0-24/MBC) and inhibitory (AUC0-24/MIC) activity to determine bacteriological response to beta-lactam antimicrobial agents, AUC0-24/MBC and AUC0-24/MIC values were compared with measured AUBC0-24 and AUIC0-24 values. Total body clearance values were equivalent for piperacillin (183.96 +/- 22.66 versus 181.72 +/- 19.54 ml/min/1.73 m2, P > 0.05) and tazobactam (184.71 +/- 19.89 versus 184.87 +/- 18.35 ml/min/1.73 m2, P > 0.05) following the administration of the 3.375-g-every-6-h and 4.5-g-every-8-h dosages, respectively. Comparison of area under the plasma concentration-time curve (AUC0-24) for piperacillin (967.74 +/- 135.56 microg x h/ml versus 978.88 +/- 140.96 microg x h/ml) and tazobactam (120.14 +/- 15.78 microg x h/ml versus 120.01 +/- 16.22 microg x h/ml) revealed no significant differences (P > 0.05) between the 3.375-g-every-6-h and 4.5-g-every-8-h regimens, respectively. Both regimens provided T > MIC values of > 60% for all organisms tested. Measured values of bactericidal (AUBC) and inhibitory (AUIC) activity were significantly different (P < 0.05) from predicted values (AUC0-24/MBC and AUC0-24/MIC) for all organisms studied with the exception of the bactericidal activity for P. aeruginosa and S. aureus. Additionally, ATCC organisms possessing the same MICs and MBCs exhibited great differences in measured AUBC0-24 and AUIC0-24 values. Reasons for this difference may be inherent differences in organism specific susceptibility.

Full Text

The Full Text of this article is available as a PDF (231.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barriere S. L., Ely E., Kapusnik J. E., Gambertoglio J. G. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985 Jul;16(1):49–59. doi: 10.1093/jac/16.1.49. [DOI] [PubMed] [Google Scholar]
  2. Batra V. K., Morrison J. A., Lasseter K. C., Joy V. A. Piperacillin kinetics. Clin Pharmacol Ther. 1979 Jul;26(1):41–53. doi: 10.1002/cpt197926141. [DOI] [PubMed] [Google Scholar]
  3. Bauer L. A., Gibaldi M. Computation of model-independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1983 Aug;72(8):978–979. doi: 10.1002/jps.2600720843. [DOI] [PubMed] [Google Scholar]
  4. Bergan T., Williams J. D. Dose dependence of piperacillin pharmacokinetics. Chemotherapy. 1982;28(3):153–159. doi: 10.1159/000238070. [DOI] [PubMed] [Google Scholar]
  5. Brismar B., Malmborg A. S., Tunevall G., Wretlind B., Bergman L., Mentzing L. O., Nyström P. O., Kihlström E., Bäckstrand B., Skau T. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother. 1992 Dec;36(12):2766–2773. doi: 10.1128/aac.36.12.2766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chow J. W., Fine M. J., Shlaes D. M., Quinn J. P., Hooper D. C., Johnson M. P., Ramphal R., Wagener M. M., Miyashiro D. K., Yu V. L. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991 Oct 15;115(8):585–590. doi: 10.7326/0003-4819-115-8-585. [DOI] [PubMed] [Google Scholar]
  7. Craig W. A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89–96. doi: 10.1016/0732-8893(95)00053-d. [DOI] [PubMed] [Google Scholar]
  8. Echols R., Weinstein M. P., O'Keeffe B., Shah A., Heller A. H. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. J Antimicrob Chemother. 1994 Jan;33(1):111–118. doi: 10.1093/jac/33.1.111. [DOI] [PubMed] [Google Scholar]
  9. Eliopoulos G. M., Klimm K., Ferraro M. J., Jacoby G. A., Moellering R. C., Jr Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):481–488. doi: 10.1016/0732-8893(89)90082-5. [DOI] [PubMed] [Google Scholar]
  10. Fass R. J., Prior R. B. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1989 Aug;33(8):1268–1274. doi: 10.1128/aac.33.8.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Flaherty J. F., Barriere S. L., Mordenti J., Gambertoglio J. G. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin. Antimicrob Agents Chemother. 1987 Jun;31(6):895–898. doi: 10.1128/aac.31.6.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hyatt J. M., Nix D. E., Schentag J. J. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother. 1994 Dec;38(12):2730–2737. doi: 10.1128/aac.38.12.2730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jacobs M. R., Aronoff S. C., Johenning S., Shlaes D. M., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1986 Jun;29(6):980–985. doi: 10.1128/aac.29.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson C. A., Halstenson C. E., Kelloway J. S., Shapiro B. E., Zimmerman S. W., Tonelli A., Faulkner R., Dutta A., Haynes J., Greene D. S. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther. 1992 Jan;51(1):32–41. doi: 10.1038/clpt.1992.5. [DOI] [PubMed] [Google Scholar]
  15. Kinzig M., Sörgel F., Brismar B., Nord C. E. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992 Sep;36(9):1997–2004. doi: 10.1128/aac.36.9.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kuck N. A., Jacobus N. V., Petersen P. J., Weiss W. J., Testa R. T. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989 Nov;33(11):1964–1969. doi: 10.1128/aac.33.11.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nicolau D. P., Nightingale C. H., Banevicius M. A., Fu Q., Quintiliani R. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996 Jan;40(1):61–64. doi: 10.1128/aac.40.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ocampo A. P., Hoyt K. D., Wadgaonkar N., Carver A. H., Puglisi C. V. Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr. 1989 Nov 10;496(1):167–179. doi: 10.1016/s0378-4347(00)82563-3. [DOI] [PubMed] [Google Scholar]
  19. Quinn J. P., Miyashiro D., Sahm D., Flamm R., Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989 Sep;33(9):1451–1456. doi: 10.1128/aac.33.9.1451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schentag J. J., Nix D. E., Adelman M. H. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP. 1991 Oct;25(10):1050–1057. doi: 10.1177/106002809102501003. [DOI] [PubMed] [Google Scholar]
  21. Schoonover L. L., Occhipinti D. J., Rodvold K. A., Danziger L. H. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination. Ann Pharmacother. 1995 May;29(5):501–514. doi: 10.1177/106002809502900510. [DOI] [PubMed] [Google Scholar]
  22. Stobberingh E. E. In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases. Chemotherapy. 1990;36(3):209–214. doi: 10.1159/000238768. [DOI] [PubMed] [Google Scholar]
  23. Sweet R. L., Roy S., Faro S., O'Brien W. F., Sanfilippo J. S., Seidlin M. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. Obstet Gynecol. 1994 Feb;83(2):280–286. [PubMed] [Google Scholar]
  24. Tan J. S., Wishnow R. M., Talan D. A., Duncanson F. P., Norden C. W. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrob Agents Chemother. 1993 Aug;37(8):1580–1586. doi: 10.1128/aac.37.8.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tjandramaga T. B., Mullie A., Verbesselt R., De Schepper P. J., Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1978 Dec;14(6):829–837. doi: 10.1128/aac.14.6.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Welling P. G., Craig W. A., Bundtzen R. W., Kwok F. W., Gerber A. U., Madsen P. O. Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother. 1983 Jun;23(6):881–887. doi: 10.1128/aac.23.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wise R., Logan M., Cooper M., Andrews J. M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084. doi: 10.1128/aac.35.6.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES